Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 78
- Reported
- 68
- Verified
- 58
- Gap
- +20
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Proceed with caution
- Why
- Genuinely the most mature sa-RNA technology - approved in Japan and the EU with superior 12-month antibody durability vs conventional mRNA - but a US regulatory block and weak real-world uptake mean the platform is approved yet not de-risked for broad deployment.
- Next
- Track real-world effectiveness/durability data and whether the FDA clinical-endpoint requirement is met; monitor EU/Japan uptake as the true adoption signal
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 0
- Tier 2
- 2
- Tier 3
- 4
- Supports
- 3
- Contradicts
- 3
- Context
- 0
- Latest observed
- 2025-10-14
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.